These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Kirkham LA; Kerr AR; Douce GR; Paterson GK; Dilts DA; Liu DF; Mitchell TJ Infect Immun; 2006 Jan; 74(1):586-93. PubMed ID: 16369015 [TBL] [Abstract][Full Text] [Related]
4. Pneumococcal virulence factors: structure and function. Jedrzejas MJ Microbiol Mol Biol Rev; 2001 Jun; 65(2):187-207 ; first page, table of contents. PubMed ID: 11381099 [TBL] [Abstract][Full Text] [Related]
5. The role of pneumolysin in the pathogenesis of Streptococcus pneumoniae infection. Cockeran R; Anderson R; Feldman C Curr Opin Infect Dis; 2002 Jun; 15(3):235-9. PubMed ID: 12015456 [TBL] [Abstract][Full Text] [Related]
6. Vaccination with a Streptococcus pneumoniae trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects against lethal pneumonia in an infant murine model. Verhoeven D; Xu Q; Pichichero ME Vaccine; 2014 May; 32(26):3205-10. PubMed ID: 24731814 [TBL] [Abstract][Full Text] [Related]
8. Studies on the structure and mechanism of a bacterial protein toxin by analytical ultracentrifugation and small-angle neutron scattering. Gilbert RJ; Heenan RK; Timmins PA; Gingles NA; Mitchell TJ; Rowe AJ; Rossjohn J; Parker MW; Andrew PW; Byron O J Mol Biol; 1999 Nov; 293(5):1145-60. PubMed ID: 10547292 [TBL] [Abstract][Full Text] [Related]
9. Review: current and new generation pneumococcal vaccines. Feldman C; Anderson R J Infect; 2014 Oct; 69(4):309-25. PubMed ID: 24968238 [TBL] [Abstract][Full Text] [Related]
10. DNA vaccines based on genetically detoxified derivatives of pneumolysin fail to protect mice against challenge with Streptococcus pneumoniae. Ferreira DM; Arêas AP; Darrieux M; Leite LC; Miyaji EN FEMS Immunol Med Microbiol; 2006 Mar; 46(2):291-7. PubMed ID: 16487311 [TBL] [Abstract][Full Text] [Related]
12. A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine. Peek LJ; Brey RN; Middaugh CR J Pharm Sci; 2007 Jan; 96(1):44-60. PubMed ID: 16998874 [TBL] [Abstract][Full Text] [Related]
13. Influence of subinhibitory concentrations of protein-synthesis-inhibiting antibiotics on production and release of the pneumococcal virulence factor pneumolysin in vitro. Spreer A; von Ruden C; Mitchell TJ; Eiffert H; Nau R Chemotherapy; 2007; 53(5):327-31. PubMed ID: 17728540 [TBL] [Abstract][Full Text] [Related]
14. Self-interaction of pneumolysin, the pore-forming protein toxin of Streptococcus pneumoniae. Gilbert RJ; Rossjohn J; Parker MW; Tweten RK; Morgan PJ; Mitchell TJ; Errington N; Rowe AJ; Andrew PW; Byron O J Mol Biol; 1998 Dec; 284(4):1223-37. PubMed ID: 9837740 [TBL] [Abstract][Full Text] [Related]
15. Pneumolysin as a vaccine and drug target in the prevention and treatment of invasive pneumococcal disease. Cockeran R; Anderson R; Feldman C Arch Immunol Ther Exp (Warsz); 2005; 53(3):189-98. PubMed ID: 15995579 [TBL] [Abstract][Full Text] [Related]
16. Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants. Ljutic B; Ochs M; Messham B; Ming M; Dookie A; Harper K; Ausar SF Vaccine; 2012 Apr; 30(19):2981-8. PubMed ID: 22381074 [TBL] [Abstract][Full Text] [Related]
17. Characterization of the solution properties and conformation of pneumolysin, the membrane-damaging toxin of Streptococcus pneumoniae. Morgan PJ; Varley PG; Rowe AJ; Andrew PW; Mitchell TJ Biochem J; 1993 Dec; 296 ( Pt 3)(Pt 3):671-4. PubMed ID: 8280065 [TBL] [Abstract][Full Text] [Related]
18. Engineering detoxified pneumococcal pneumolysin derivative ΔA146PLY for self-biomineralization of calcium phosphate: Assessment of their protective efficacy in murine infection models. Wu J; Wu K; Xu W; Yuan T; Wang X; Zhang J; Min Y; Yin Y; Zhang X Biomaterials; 2018 Feb; 155():152-164. PubMed ID: 29179131 [TBL] [Abstract][Full Text] [Related]
19. Exploitation of physiology and metabolomics to identify pneumococcal vaccine candidates. Schulz C; Hammerschmidt S Expert Rev Vaccines; 2013 Sep; 12(9):1061-75. PubMed ID: 24053399 [TBL] [Abstract][Full Text] [Related]
20. Pneumococcal conjugate vaccine for young children. Selman S; Hayes D; Perin LA; Hayes WS Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]